Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Anesthesiology

Open Access

Update of the quality assurance (QA) results of halothane and caffeine analysis of all current participating malignant hyperthermia units

  • Nickla Fisher1,
  • Helena Wright1 and
  • Philip Hopkins1
BMC Anesthesiology201414(Suppl 1):A5

https://doi.org/10.1186/1471-2253-14-S1-A5

Published: 18 August 2014

Background

The provision of a Quality Assurance Scheme for members of the European Malignant Hyperthermia Group (EMHG) is to ensure that the concentrations of halothane and caffeine in the tissue bath are as stipulated in the in vitro contracture test (IVCT) protocol. Confirmation of the correct concentrations in the tissue bath is an essential part of the IVCT protocol.

The focus of this presentation will be to provide an update of the QA results from the analysis of both halothane and caffeine from all of the participating units over a period of three years.

The aims are to show
  1. 1.

    How many malignant hyperthermia (MH) units have achieved the target concentrations of halothane for nominal vaporiser settings of 0.5% (0.11mM) and 2.0% (0.44mM) and caffeine concentrations of 0.5mM and 2.0mM?

     
  2. 2.

    How these halothane concentrations can vary within each lab?

     

Results

Each lab is aware of its own results. Anonymised results from January 2012 to January 2014 will be presented from each participating MH unit.

These will include halothane results for vaporiser settings of 0.5% and 2.0%. The tissue bath concentration is usually lower than the required concentration, but halothane concentrations can also be found to be higher. Halothane concentrations can also vary within each lab.

Caffeine analysis results collected over the past 24 months will also be presented from each participating lab.

Authors’ Affiliations

(1)
Leeds Institute of Molecular Medicine, St James's University Hospital

Copyright

© Fisher et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement